Dr Bizzari (62) has served as EVP, Group Head, and Clinical Oncology Development (US, Europe, and Asia/Japan) at Celgene from 2008 to 2015. He has 15 years’ experience as Vice President clinical development at Rhone Poulenc Rorer, Aventis, Sanofi-Aventis and has been involved in the clinical development of several anticancer agents such as Taxotere®, Eloxatin®, Revlimid®, Vidaza®, Abraxane®, Irinotecan® (CPT-11). Dr Bizzari is a world-renowned oncology expert and is a member of the scientific advisory board of the French National Cancer Institute (INCa), and European Organisation of Research and Treatment of Cancer (EORTC) as chair of the new drug advisory committee. He serves as director of the boards of several biotech companies; Transgene, Onxeo, Iteos, Halozyme Therapeutics and Pieris Pharmaceuticals. Dr Bizzari has published more than 70 articles in peer-reviewed journals and more than 160 abstracts in scientific congresses. He joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). Dr Bizzari holds a medical degree specialised in oncology from the University of Nice (France) and has trained successively at the Pitié-Salpêtrière hospital in Paris, at Ontario Cancer Institute, and Montreal Mac Gill Cancer Center in Canada. He is a French and US citizen and resides in the US. He has served as a director in the company since May 2016. Dr Bizzari is an independent director of the board. He attended 10 board meetings in 2016.

Clinical Oncology, anticancer agents,oncology